Deborah A. Katz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Deborah A. Katz has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Ira J Miller
2 shared publicationsLydia Usha
Division of Hematology and Oncology, Department of Medicine, Rush University Medical Center, Chicago, Illinois
2 shared publicationsStephanie A Gregory
2 shared publicationsAbraham A. Anderson
Amgen Inc, Thousand Oaks, CA, USA
1 shared publicationAlejandro Martín García-Sancho
Hospital Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain
1 shared publication- Andreas Viardot
Department of Internal Medicine III, University Hospital, Ulm, Germany
1 shared publication
Latest Publications
- Open Access
- 31 October 2022
- Published by Elmer Press, Inc. in Journal of Medical Cases
- Vol. 13 (10) , 521-524
Iatrogenic Immunodeficiency Associated Lymphoproliferative Disorder in a Patient With Inflammatory Bowel Disease
Primary colorectal lymphoma is incredibly rare and cases of iatrogenic immunodeficiency associated lymphoproliferative disorder (IILPD) isolated to colorectal area are even more uncommon. Immunodeficiency associated lymphoproliferative disorders can occur in association with primary immune disorders such as inflammatory bowel diseases (IBDs) which are often treated with various immunomodulatory drugs. Of the immunomodulatory drugs, thiopurines, in particular, are known to have a significantly increased relative risk for development of IILPDs. Here we present the case of a 43-year-old Caucasian man with a 22-year history of IBD treated with longstanding immunomodulatory therapy who presented with severe rectal pain and drainage. He underwent an examination under anesthesia with rigid proctoscopy and biopsies were taken of a hard exophytic appearing tissue along the posterior wall of the rectosigmoid junction. Pathological investigation of the samples revealed IILPD. He underwent treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) and achieved complete remission. Literature demonstrates that the use of immunomodulators such as azathioprine has been shown to significantly improve the quality of life in patients with IBD. However, while the absolute risk of lymphoma for any given patient remains quite low, the relative risk of lymphoma in patients who are actively treated with thiopurines is moderate. Therefore, the decision to proceed with thiopurine treatment, especially in the setting of long-term therapy, requires extensive discussion and patient education of the risks/benefits along with closer monitoring of new or uncharacteristic symptoms. J Med Cases. 2022;13(10):521-524 doi: https://doi.org/10.14740/jmc3798
- 31 October 2022
- Published by Elmer Press, Inc. in Journal of Medical Cases
- Vol. 13 (10) , 521-524
Open AccessIatrogenic Immunodeficiency Associated Lymphoproliferative Disorder in a Patient With Inflammatory Bowel Disease
Primary colorectal lymphoma is incredibly rare and cases of iatrogenic immunodeficiency associated lymphoproliferative disorder (IILPD) isolated to colorectal area are even more uncommon. Immunodeficiency associated lymphoproliferative disorders can occur in association with primary immune disorders such as inflammatory bowel diseases (IBDs) which are often treated with various immunomodulatory drugs. Of the immunomodulatory drugs, thiopurines, in particular, are known to have a significantly increased relative risk for development of IILPDs. Here we present the case of a 43-year-old Caucasian man with a 22-year history of IBD treated with longstanding immunomodulatory therapy who presented with severe rectal pain and drainage. He underwent an examination under anesthesia with rigid proctoscopy and biopsies were taken of a hard exophytic appearing tissue along the posterior wall of the rectosigmoid junction. Pathological investigation of the samples revealed IILPD. He underwent treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) and achieved complete remission. Literature demonstrates that the use of immunomodulators such as azathioprine has been shown to significantly improve the quality of life in patients with IBD. However, while the absolute risk of lymphoma for any given patient remains quite low, the relative risk of lymphoma in patients who are actively treated with thiopurines is moderate. Therefore, the decision to proceed with thiopurine treatment, especially in the setting of long-term therapy, requires extensive discussion and patient education of the risks/benefits along with closer monitoring of new or uncharacteristic symptoms. J Med Cases. 2022;13(10):521-524 doi: https://doi.org/10.14740/jmc3798
- Open Access
- 3 May 2022
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 63 (9) , 2063-2073
Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL
This open-label, multicenter, single-arm, phase 2 study assessed the safety and efficacy of blinatumomab consolidation therapy in adult patients with newly diagnosed, high-risk diffuse large B-cell lymphoma (DLBCL; International Prognostic Index 3–5 and/or double-/triple-hit or double MYC/BCL-2 expressors) who achieved complete response (CR), partial response (PR), or stable disease (SD) following run-in with 6 cycles of R-chemotherapy (NCT03023878). Of the 47 patients enrolled, 28 received blinatumomab. Five patients (17.9%) experienced grade 4 treatment-emergent adverse events of interest (neutropenia, n = 4; infection, n = 1). Two deaths reported at the end of the study were unrelated to treatment with blinatumomab (disease progression, n = 1; infection, n = 1). 3/4 patients with PR and 4/4 patients with SD after R-chemotherapy achieved CR following blinatumomab. Consolidation with blinatumomab in patients with newly diagnosed, high-risk DLBCL who did not progress under R-chemotherapy was better tolerated than in previous studies where blinatumomab was used for treatment of patients with lymphoma.
- 3 May 2022
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 63 (9) , 2063-2073
Open AccessOpen-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL
This open-label, multicenter, single-arm, phase 2 study assessed the safety and efficacy of blinatumomab consolidation therapy in adult patients with newly diagnosed, high-risk diffuse large B-cell lymphoma (DLBCL; International Prognostic Index 3–5 and/or double-/triple-hit or double MYC/BCL-2 expressors) who achieved complete response (CR), partial response (PR), or stable disease (SD) following run-in with 6 cycles of R-chemotherapy (NCT03023878). Of the 47 patients enrolled, 28 received blinatumomab. Five patients (17.9%) experienced grade 4 treatment-emergent adverse events of interest (neutropenia, n = 4; infection, n = 1). Two deaths reported at the end of the study were unrelated to treatment with blinatumomab (disease progression, n = 1; infection, n = 1). 3/4 patients with PR and 4/4 patients with SD after R-chemotherapy achieved CR following blinatumomab. Consolidation with blinatumomab in patients with newly diagnosed, high-risk DLBCL who did not progress under R-chemotherapy was better tolerated than in previous studies where blinatumomab was used for treatment of patients with lymphoma.
- 1 March 2015
- Published by Elsevier in Practical Radiation Oncology
- Vol. 5 (2) , e61-e65
Radiosensitizing effect of anti-HER2/neu agents: Report of 2 cases and review of the literature
- 1 March 2015
- Published by Elsevier in Practical Radiation Oncology
- Vol. 5 (2) , e61-e65
Radiosensitizing effect of anti-HER2/neu agents: Report of 2 cases and review of the literature
- 1 February 2013
- Vol. 11 (2) , 109-13
Successful treatment of hepatosplenic T-cell lymphoma with ESHAP followed by autologous stem cell transplant.
- 1 February 2013
- Vol. 11 (2) , 109-13
Successful treatment of hepatosplenic T-cell lymphoma with ESHAP followed by autologous stem cell transplant.
- Open Access
- 1 June 2012
- Published by Taylor & Francis in Orphan Drugs: Research and Reviews
Potential role of enzastaurin in the treatment of patients with relapsed or refractory advanced cutaneous T-cell lymphomas: a review
Peer reviewed article authored by (Katz DA, Plate JM, Nathan S, Usha L). Read article or submit your manuscript for publishing.
- 1 June 2012
- Published by Taylor & Francis in Orphan Drugs: Research and Reviews
Open AccessPotential role of enzastaurin in the treatment of patients with relapsed or refractory advanced cutaneous T-cell lymphomas: a review
Peer reviewed article authored by (Katz DA, Plate JM, Nathan S, Usha L). Read article or submit your manuscript for publishing.
- 1 September 2010
- Vol. 8 (9) , 637-41
Intravascular B-cell lymphoma following nodal diffuse large B-cell lymphoma.
- 1 September 2010
- Vol. 8 (9) , 637-41
Intravascular B-cell lymphoma following nodal diffuse large B-cell lymphoma.